First-in-class lanthipeptide GPCR agonists

Lanthionine-constrained peptides
have superior target selectivity and stability

Welcome to Lanthio Pharma

Lanthio Pharma is a Dutch biopharmaceutical company committed to discovering and developing therapeutic peptides for severe diseases with high unmet medical need. With its proprietary technologies, the company is generating lanthionine-constrained peptides with superior target-selectivity and stability.

Utilizing our technology we are building a growing pipeline of receptor-specific, stabilized lanthipeptides in oncology and critical-care medicine.

16/11/2020
Today, the shares of Lanthio Pharma B.V., owned by MorphoSys AG, have been...
19/12/2017
Lanthio Pharma and MorphoSys scientists publish lanthipeptide phage...
19/05/2017
MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide...
21/02/2017
MorphoSys’s Subsidiary Lanthio Pharma Initiates First-in-Human Clinical...
19/09/2016
Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed...
07/05/2015
MorphoSys Acquires Lanthio Pharma
21/11/2014
Lanthio Pharma Receives Gouden KIEM Award as Dutch Chemical Start-up of...
15/10/2014
MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma
18/06/2014
Lanthio Pharma announces change of CEO
21/05/2014
Lanthio Pharma receives Dutch Government loan of up to €3.6 million to...